DexCom, Inc. $DXCM Shares Acquired by Two Sigma Securities LLC

Two Sigma Securities LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 173.6% during the second quarter, HoldingsChannel.com reports. The firm owned 8,895 shares of the medical device company’s stock after purchasing an additional 5,644 shares during the period. Two Sigma Securities LLC’s holdings in DexCom were worth $599,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Plato Investment Management Ltd acquired a new stake in shares of DexCom in the 2nd quarter worth $782,000. BOKF NA raised its holdings in shares of DexCom by 175.7% in the 4th quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock valued at $2,344,000 after buying an additional 22,505 shares during the period. Stephens Investment Management Group LLC lifted its position in shares of DexCom by 21.1% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock worth $69,211,000 after purchasing an additional 181,701 shares in the last quarter. Norges Bank acquired a new position in shares of DexCom in the fourth quarter worth $483,356,000. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in DexCom during the 4th quarter worth about $3,231,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

DXCM stock opened at $90.14 on Wednesday. The stock has a 50-day moving average price of $80.07 and a two-hundred day moving average price of $71.93. The company has a market cap of $34.02 billion, a PE ratio of 35.63, a price-to-earnings-growth ratio of 1.54 and a beta of 1.42. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same quarter last year, the firm posted $0.48 earnings per share. DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, research analysts predict that DexCom, Inc. will post 2.64 EPS for the current year.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 2,565 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $88.37, for a total value of $226,669.05. Following the transaction, the executive vice president directly owned 126,043 shares of the company’s stock, valued at $11,138,419.91. This represents a 1.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of DexCom stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $85.32, for a total value of $170,640.00. Following the completion of the transaction, the director owned 48,852 shares of the company’s stock, valued at $4,168,052.64. This trade represents a 3.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 70,688 shares of company stock valued at $5,314,766 over the last three months. Company insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DXCM. Robert W. Baird set a $105.00 price objective on DexCom in a research report on Friday, July 31st. Wells Fargo & Company upped their price objective on DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. William Blair raised shares of DexCom to a “strong-buy” rating in a report on Friday, May 15th. Wall Street Zen lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Barclays reaffirmed an “underweight” rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $88.71.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.